[{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"aa19e127-4a6d-4543-94a8-fa9ef6096cb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881525","created_at":"2023-05-31T15:05:39.768Z","updated_at":"2024-07-02T16:35:09.880Z","phase":"Phase 1","brief_title":"NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05881525","lead_sponsor":"TCRCure Biopharma Ltd.","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-12"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"0ad7e2a2-55da-4a09-ae90-1310e59dd275","acronym":"NCI-2018-01758","url":"https://clinicaltrials.gov/study/NCT03691376","created_at":"2021-01-19T16:42:01.861Z","updated_at":"2024-07-02T16:35:15.468Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03691376 - NCI-2018-01758","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 03/08/2019","start_date":" 03/08/2019","primary_txt":" Primary completion: 01/30/2021","primary_completion_date":" 01/30/2021","study_txt":" Completion: 01/24/2027","study_completion_date":" 01/24/2027","last_update_posted":"2024-03-11"},{"id":"96478ee8-ea1d-46f0-9076-86b0a0a5b146","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869217","created_at":"2021-02-16T02:53:03.033Z","updated_at":"2024-07-02T16:35:26.728Z","phase":"Phase 1","brief_title":"Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","source_id_and_acronym":"NCT02869217","lead_sponsor":"University Health Network, Toronto","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-08"},{"id":"2af4501d-3698-4fa1-bef4-a73d1a7b2ae3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250325","created_at":"2021-02-16T02:53:12.531Z","updated_at":"2024-07-02T16:35:26.928Z","phase":"Phase 1/2","brief_title":"Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma","source_id_and_acronym":"NCT03250325","lead_sponsor":"Takara Bio Inc.","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 03/09/2022","study_completion_date":" 03/09/2022","last_update_posted":"2023-12-06"},{"id":"4cfc19cf-1a63-442c-b2f4-a73392edd470","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939701","created_at":"2021-06-25T22:54:10.185Z","updated_at":"2024-07-02T16:35:29.993Z","phase":"Phase 1/2","brief_title":"Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants","source_id_and_acronym":"NCT04939701","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1 • CTAG1B • SSX1","pipe":" | ","alterations":" CTAG1B expression","tags":["PD-L1 • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP0739"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-11-08"},{"id":"0ed959af-c2b5-458e-b542-28311d0168e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063632","created_at":"2021-01-18T15:05:12.923Z","updated_at":"2024-07-02T16:35:31.715Z","phase":"Phase 2","brief_title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","source_id_and_acronym":"NCT03063632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["IFNG • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-10-25"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"bdb8eace-af07-466b-a0e7-cc3562eb74f5","acronym":"ADP-0011-007","url":"https://clinicaltrials.gov/study/NCT02992743","created_at":"2021-02-16T02:53:04.030Z","updated_at":"2024-07-02T16:35:50.904Z","phase":"Phase 2","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma","source_id_and_acronym":"NCT02992743 - ADP-0011-007","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-04-11"},{"id":"6cd6fea1-b47e-41c8-8a34-ff357b707a61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737787","created_at":"2021-01-18T13:24:34.815Z","updated_at":"2024-07-02T16:35:51.110Z","phase":"Phase 1","brief_title":"A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02737787","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MUC16 • CTAG1B","pipe":" | ","alterations":" WT1 expression • CTAG1B expression • WT1 positive","tags":["WT1 • MUC16 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • CTAG1B expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-07"},{"id":"29cb0858-fdb9-4eb6-80b7-ac58c084f489","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199849","created_at":"2021-01-18T00:40:45.229Z","updated_at":"2024-07-02T16:36:02.775Z","phase":"Phase 1","brief_title":"NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine","source_id_and_acronym":"NCT00199849","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression","tags":["CD8 • CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/27/2004","start_date":" 09/27/2004","primary_txt":" Primary completion: 09/11/2006","primary_completion_date":" 09/11/2006","study_txt":" Completion: 09/01/2007","study_completion_date":" 09/01/2007","last_update_posted":"2022-10-10"},{"id":"cd953313-4922-4eb7-86f4-86fd680fb3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299728","created_at":"2021-01-18T01:01:31.071Z","updated_at":"2024-07-02T16:36:02.802Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","source_id_and_acronym":"NCT00299728","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression • CTAG2 expression","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/21/2006","start_date":" 03/21/2006","primary_txt":" Primary completion: 10/10/2006","primary_completion_date":" 10/10/2006","study_txt":" Completion: 01/10/2014","study_completion_date":" 01/10/2014","last_update_posted":"2022-10-10"},{"id":"4b902844-e9bb-481c-9882-6b4cdce12c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT04878484","created_at":"2021-05-07T11:53:02.821Z","updated_at":"2024-07-02T16:36:04.497Z","phase":"Phase 1","brief_title":"Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04878484","lead_sponsor":"Athenex, Inc.","biomarkers":" CD8 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CTAG1B expression","tags":["CD8 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TCRT-ESO-A2"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-02"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"371e00b7-13f0-4e7a-9ae5-dfcb18a5df87","acronym":"ADP 04511","url":"https://clinicaltrials.gov/study/NCT01343043","created_at":"2021-02-16T02:52:18.139Z","updated_at":"2024-07-02T16:36:28.459Z","phase":"Phase 1","brief_title":"A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma","source_id_and_acronym":"NCT01343043 - ADP 04511","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/27/2012","start_date":" 09/27/2012","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2021-06-30"},{"id":"41000dfd-c03d-4b57-8024-e57a425d66f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01213472","created_at":"2021-01-18T04:52:16.779Z","updated_at":"2024-07-02T16:36:54.740Z","phase":"Phase 1","brief_title":"Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT01213472","lead_sponsor":"GlaxoSmithKline","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2241658A"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/31/2011","start_date":" 01/31/2011","primary_txt":" Primary completion: 04/17/2018","primary_completion_date":" 04/17/2018","study_txt":" Completion: 04/17/2018","study_completion_date":" 04/17/2018","last_update_posted":"2019-10-09"},{"id":"2b0121ff-99c4-4030-9c8c-850dfc76191c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01567891","created_at":"2021-02-16T02:52:20.305Z","updated_at":"2024-07-02T16:36:58.558Z","phase":"Phase 1/2","brief_title":"CT Antigen TCR-redirected T Cells for Ovarian Cancer.","source_id_and_acronym":"NCT01567891","lead_sponsor":"Adaptimmune","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 06/06/2017","primary_completion_date":" 06/06/2017","study_txt":" Completion: 06/06/2017","study_completion_date":" 06/06/2017","last_update_posted":"2019-06-27"},{"id":"e873d956-13ab-48aa-a169-caf94edb28e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122861","created_at":"2021-02-14T06:08:06.372Z","updated_at":"2024-07-02T16:37:02.194Z","phase":"Phase 1","brief_title":"Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1","source_id_and_acronym":"NCT02122861","lead_sponsor":"Immune Design","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ID-LV305"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/30/2014","start_date":" 05/30/2014","primary_txt":" Primary completion: 11/14/2018","primary_completion_date":" 11/14/2018","study_txt":" Completion: 12/15/2018","study_completion_date":" 12/15/2018","last_update_posted":"2019-03-06"},{"id":"d5aa3cc3-f529-4b63-b742-7f0b390e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03029273","created_at":"2021-01-18T14:54:32.246Z","updated_at":"2024-07-02T16:37:03.751Z","phase":"Phase 1","brief_title":"NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC","source_id_and_acronym":"NCT03029273","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" EGFR • ALK • CTAG1B","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • CTAG1B expression","tags":["EGFR • ALK • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAEST16001 • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/21/2017","start_date":" 03/21/2017","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-01-17"},{"id":"bc490f3e-ae39-4b4d-8c5b-7cc4684c6d84","acronym":"","url":"https://clinicaltrials.gov/study/NCT02366546","created_at":"2021-02-16T02:52:35.194Z","updated_at":"2024-07-02T16:37:05.826Z","phase":"Phase 1","brief_title":"Investigator Initiated Phase 1 Study of TBI-1301","source_id_and_acronym":"NCT02366546","lead_sponsor":"Mie University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":"","study_completion_date":"","last_update_posted":"2018-10-24"},{"id":"27f7def0-0a3d-41d2-a3fc-8aec054ca22f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01079741","created_at":"2021-01-18T04:15:28.413Z","updated_at":"2024-07-02T16:37:13.945Z","phase":"Phase 2","brief_title":"Safety Study of Adjuvant Vaccine to Treat Melanoma Patients","source_id_and_acronym":"NCT01079741","lead_sponsor":"Nina Bhardwaj","biomarkers":" CD8 • CTAG1B • CD4","pipe":" | ","alterations":" CD8 expression • CTAG1B expression","tags":["CD8 • CTAG1B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 03/11/2013","primary_completion_date":" 03/11/2013","study_txt":" Completion: 03/11/2013","study_completion_date":" 03/11/2013","last_update_posted":"2018-02-13"},{"id":"fbcfc826-1fcb-464e-89b3-ff2e4a431d11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02015416","created_at":"2021-02-14T06:07:24.302Z","updated_at":"2024-07-02T16:37:18.747Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer","source_id_and_acronym":"NCT02015416","lead_sponsor":"Immune Design","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDC-G305 • glucopyranosyl lipid A (G100)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2017-08-17"},{"id":"90fb6027-621c-4dc6-9ea8-cc3e46aa43e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00819806","created_at":"2021-02-16T02:52:12.218Z","updated_at":"2024-07-02T16:37:19.374Z","phase":"Phase 1","brief_title":"CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors","source_id_and_acronym":"NCT00819806","lead_sponsor":"Hassane M. Zarour, MD","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Promune (agatolimod) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2017-07-31"}]